Drug Shortage Report for SANDOZ RIVASTIGMINE
Report ID | 74710 |
Drug Identification Number | 02324571 |
Brand name | SANDOZ RIVASTIGMINE |
Common or Proper name | RIVASTIGMINE |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | RIVASTIGMINE |
Strength(s) | 3MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL |
Packaging size | 4X14/bl |
ATC code | N06DA |
ATC description | ANTI-DEMENTIA DRUGS |
Reason for shortage | Requirements related to complying with good manufacturing practices. |
Anticipated start date | |
Actual start date | 2019-01-23 |
Estimated end date | 2019-03-18 |
Actual end date | 2019-03-22 |
Shortage status | Resolved |
Updated date | 2019-04-10 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v10 | 2019-04-10 | French | Compare |
v9 | 2019-04-10 | English | Compare |
v8 | 2019-03-13 | French | Compare |
v7 | 2019-03-13 | English | Compare |
v6 | 2019-03-05 | French | Compare |
v5 | 2019-03-05 | English | Compare |
v4 | 2019-02-18 | French | Compare |
v3 | 2019-02-18 | English | Compare |
v2 | 2019-02-04 | French | Compare |
v1 | 2019-02-04 | English | Compare |
Showing 1 to 10 of 10